Notice of Special Interest: Innovative Approaches or Technologies to Investigate Regional, Structural and Functional Heterogeneity of CNS Small Blood and Lymphatic Vessels in AD/ADRD (NOT-NS-21-039)

Sponsor: National Institute of Neurological Disorders and Stroke

Due Date: May 5, 2021, by 5 p.m. local time of applicant organization.

Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed) (PAR-21-122)

Sponsor: National Institute of Neurological Disorders and Stroke

NIH-IRACDA Postdoctoral Fellowships: 70% Minority Brain Health Research, 30% Minority Undergraduate Training

Sponsor: Rutgers University / National Institute of General Medical Sciences

Due Date: May 1

Institutional Research and Academic Career Development Awards (IRACDA) (K12)

Sponsor: National Institute of General Medical Sciences

Triadic Interactions in Clinical Encounters Involving People with Alzheimer's Disease and Alzheimer's Disease-Related Dementias (AD/ADRD), Clinicians, and Care Partners (R01 Clinical Trial Optional) (

Sponsor: National Institute on Aging

Award: NIA intends to commit $1.87 million in FY 2022 to fund three to four awards.

Due Date: June 23, 2021

Notice of Special Interest (NOSI): Administrative Supplements for Research on Womens Health in the IDeA States (NOT-GM-21-018)

Sponsor: National Institutes of Health

Notice of Special Interest (NOSI): Translation of BRAIN Initiative Technologies to the Marketplace (NOT-MH-21-125)

Sponsor: National Institutes of Health

AD/ADRD Clinical Trials Short Course (R25 Independent Clinical Trial Not Allowed) (PAR-21-141)

Sponsor: National Institute on Aging

Award: NIH intends to fund a maximum of five awards corresponding to a total of $1.8 million for fiscal year 2022. Future amounts will depend on annual appropriations.

Due Date: May 25, 2021; May 25, 2022; May 25, 2023

Notice of Intent to Publish a Funding Opportunity Announcement for Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (UG3/UH3

Sponsor: National Institutes of Health

Notice of Intent to Publish a Funding Opportunity Announcement for Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (U44 Cli

Sponsor: National Institutes of Health

Notice of Special Interest (NOSI): Neurological and Neurocognitive Sequelae from SARS-CoV-2 Infection and COVID-19 in Aging and Age-Related Neurodegeneration (NOT-AG-21-016)

Sponsor: National Institute on Aging

Maximizing Access to Research Careers (T34 - Clinical Trial Not Allowed) (PAR-21-147)

Sponsor: National Institute of General Medical Sciences

Due Date: May 26, 2021; May 26, 2022; May 26, 2023

NINDS Institutional Research Training Program (T32 - Clinical Trial Not Allowed) (PAR-21-149)

Sponsor: National Institute of Neurological Disorders and Stroke

Due Date: May 25, 2021, May 25, 2022, May 25, 2023

ADDF-Harrington Scholar Program

Sponsor: Alzheimer’s Drug Discovery Foundation (ADDF)

Award: Up to $600,000 over two years.

Due Date: Letter of Intent: April 23rd, 2021, 5 p.m. EDT. Full Proposal: July 30, 2021, 5 p.m. EDT.

Efficient and Innovative Natural History Studies Addressing Unmet Needs in Rare Diseases (R01) Clinical Trials Not Required (RFA-FD-22-001)

Sponsor: Food and Drug Administration

Due Date: February 15, 2022; February 13, 2024: by 11:59 PM Eastern time.